University Health Network, University of Toronto, Toronto, Canada.
J Hepatol. 2011 Jul;55(1):207-17. doi: 10.1016/j.jhep.2010.11.012. Epub 2010 Nov 29.
Hepatitis C virus (HCV) re-infection of the graft is universal and interferon based antiviral therapy remains at present the treatment of choice in HCV liver transplant recipients. Apart from the antiviral effects, interferon and ribavirin have both potent immunomodulatory properties resulting in a broad range of immune-related disorders including acute cellular rejection and chronic ductopenic rejection as well as de novo autoimmune hepatitis. Further complicating the picture, HCV infection per se is associated with a variety of autoimmune phenomena. We discuss here the immune-mediated complications and their relationship to chronic HCV and interferon based antiviral therapy.
丙型肝炎病毒（HCV）对移植物的再感染是普遍存在的，目前基于干扰素的抗病毒治疗仍然是 HCV 肝移植受者的治疗选择。除了抗病毒作用外，干扰素和利巴韦林都具有很强的免疫调节特性，导致广泛的免疫相关疾病，包括急性细胞排斥和慢性胆管缺失性排斥以及新的自身免疫性肝炎。更复杂的是，HCV 感染本身与多种自身免疫现象有关。我们在这里讨论免疫介导的并发症及其与慢性 HCV 和基于干扰素的抗病毒治疗的关系。
